SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending due to concerns surrounding a potential government shutdown, with the community debating its potential impact on the market. Some traders anticipate a buying opportunity amidst the uncertainty, while others foresee a significant market correction, drawing parallels to past shutdowns and economic conditions. Community sentiment is divided between those expecting a quick resolution and those bracing for prolonged volatility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amidst discussions around a potential government shutdown and its implications, with the community debating the roles of different political parties. Some investors are focused on the potential for federal job cuts, while others are discussing the financial implications of tariffs and government spending. There's also chatter regarding the stock's valuation and comparisons to other meme stocks.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid concerns of a potential government shutdown, with the community debating its impact and possible market pullbacks. Some traders believe a shutdown is priced in or could even be bullish, while others brace for a significant dip, drawing parallels to historical market reactions and potential economic consequences. Despite the uncertainty, the overall sentiment remains divided, with some anticipating new all-time highs while others prepare for increased volatility.

Lithium Americas Corp. engages in the development of the Thacker Pass project. It is focused on advancing Thacker Pass to production it is located in northern Nevada. The company was founded on January 23, 2023 and is headquartered in Vancouver, Canada.

Lithium Americas Corp (NewCo)

Lithium Americas Corp

Lithium Americas Corp is trending following reports that the U.S. government will take a stake in the company, specifically in its Thacker Pass project, to boost domestic lithium production. The community is discussing the potential for a short squeeze and comparing it to similar government-backed plays, speculating on price targets and the impact on U.S. energy independence.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the community discusses potential catalysts like upcoming ETF decisions and the impact of a possible government shutdown on the crypto market. Discussions include speculation on whale activity, supply dynamics, and price predictions for October. Some traders are weighing positive developments against concerns around competition and historical price performance.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as its community rallies around its active development and upcoming utilities like staking and a mobile gambling app. The community is focused on grinding, and working toward the next coin burn event, while highlighting the coin's listing on Bifinance. $BROKE holders see it as more than a meme, with some calling it a survivor in the Solana ecosystem.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

$BYTE.X is trending as a community-driven token potentially linked to xAI and Elon Musk, with community members highlighting its strong base and potential as a meme coin. The community is actively promoting the token, emphasizing its potential for significant growth and comparing it to other meme coins.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending following a surprise earnings beat and revenue growth, signaling a potential turnaround. The community is weighing positive Q1 results against concerns about tariffs, declining margins, and the impact of a possible government shutdown. Some analysts are raising price targets, while others remain cautious, pointing to ongoing challenges and a high valuation.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal ($PYPL) is trending amid discussions about its valuation, growth prospects, and competition from companies like Stripe. Community members are debating whether the stock is undervalued or a value trap, with some expressing frustration over its performance and others optimistic about its long-term potential, including the growth of PYUSD. Additionally, some traders are closely watching key technical levels and unusual options activity for potential trading opportunities.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending, with community members touting it as a movement for digital freedom and innovation, emphasizing its unique culture and vision. Conversation highlights Weedcoin's aim to empower creators and disrupt conventional norms within the crypto space. Amidst the enthusiasm, some users express skepticism, questioning the coin's utility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure

Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.

Soleno Therapeutics (SLNO) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Soleno Therapeutics (SLNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Shares of Soleno Therapeutics (SLNO) tumbled 14% on Wednesday following the news of the death of a patient treated with the company’s Vykat XR drug.The company stated in a filing with the Securities and Exchange Commission that it is aware of a serious adverse event reported in the U.S. Food and Drug Administration’s (FDA) Adverse Event Reporting System (FAERS) involving a deceased patient. However, the existence of a report in the data does not establish causation, the company said.Soleno said that its assessment of the death is the same as the treating physician, who said that the death is not related to the treatment with Vykat XR. The 17-year-old boy had a history of comorbidities, including lymphedema, superficial thrombophlebitis, and obesity, the company said, while adding that he died from an apparent pulmonary embolus.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001484565/000119312525199882/d88981d8k.htm">said</a> that Vykat XR has a proven safety and efficacy profile and was approved by the FDA following a rigorous clinical program.“Going forward, Soleno does not intend to specifically comment on adverse events cases (including deaths) unless directly related to VYKAT XR use and unexpected per the U.S. Prescribing Information,” the company stated, while adding that the patient population treated with Vykat XR has significant comorbidities and a markedly reduced life expectancy.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SLNO">SLNO stock</a> stayed within ‘bearish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:624/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_10_at_2_04_40_PM_png_3f94f5b623.webp" alt="SLNO's Sentiment Meter and Message Volume as of 2:05 p.m. ET on Sept. 10, 2025 | Source: Stocktwits" width="624" height="62"><figcaption>SLNO's Sentiment Meter and Message Volume as of 2:05 p.m. ET on Sept. 10, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user hinted they are exiting their position.<stembedurl>https://stocktwits.com/Mik21212/message/628184514</stembedurl>Another user, however, highlighted that the death was unrelated to the drug.<stembedurl>https://stocktwits.com/Zzzquil/message/628178500</stembedurl>Soleno <a href="https://stocktwits.com/news-articles/markets/equity/soleno-therapeutics-gets-fda-approval-for-prader-willi-syndrome-drug/chJ25DRRbE3">received</a> the U.S. Food and Drug Administration’s approval for Vykat XR extended-release tablets for the treatment of hyperphagia in patients four years of age and older with Prader-Willi syndrome in March and subsequently launched it in April. Vykat XR is the company’s first commercial product.Prader-Willi syndrome is a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15, estimated to occur in one in every 15,000 live births. The disorder is defined by hyperphagia, an intense, persistent sensation of hunger, which could be life-threatening.Last month, Scorpion Capital <a href="https://stocktwits.com/news-articles/markets/equity/soleno-therapeutics-stock-slumps-after-scorpion-capital-reveals-short-position/chsPUzYRdfU">revealed</a> a short position on the stock, alleging several risks associated with Vykat XR, including high risk of pre-diabetes/diabetes, pulmonary edema, and congestive heart failure. Scorpion Capital also stated that it intends to submit an emergency Citizen Petition shortly, requesting that the FDA urge Soleno to conduct a voluntary recall of Vykat XR from the market.SLNO stock is up 34% this year and approximately 22% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-and-hers-stock-rises-after-company-launches-treatment-plans-for-low-testosterone/chwkjBwRduy">Hims &amp; Hers Stock Rises After Company Launches Treatment Plans For Low Testosterone</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Soleno Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Soleno Therapeutics Stock Tanks After Patient Treated With Drug Dies – More Details Inside

Soleno said that its assessment of the death is the same as the treating physician, who said that the death is not related to the treatment with Vykat XR.

Equity

Soleno said that its assessment of the death is the same as the treating physician, who said that the death is not related to the treatment with Vykat XR.


Down 21.7% in 4 Weeks, Here's Why Soleno Therapeutics (SLNO) Looks Ripe for a Turnaround 

The heavy selling pressure might have exhausted for Soleno Therapeutics (SLNO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Shares of Soleno Therapeutics (SLNO) slumped 7% on Friday afternoon after Scorpion Capital revealed a short position on the stock, citing risks associated with the company’s drug approved for Prader-Willi syndrome.The shortseller alleged several risks associated with Vykat XR, including high risk of pre-diabetes/diabetes, pulmonary edema, and congestive heart failure. It further alleged that the drug may be at risk of being withdrawn from the market, or new prescriptions may plunge.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SLNO">Soleno</a> trended in the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:1366/124;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_15_at_12_42_29_PM_png_0f8718e0b7.webp" alt="SLNO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Aug. 15, 2025 | Source: Stocktwits" width="1366" height="124"><figcaption>SLNO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Aug. 15, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user dismissed the short seller report, citing inconsistencies with public data.<stembedurl>https://stocktwits.com/aristocks/message/625341208</stembedurl>Another believes the stock is a good buy-the-dip candidate.<stembedurl>https://stocktwits.com/CrispDry/message/625323181</stembedurl>Scorpion Capital said in its report that Soleno is reminiscent of the company Zafgen, which announced two patient deaths in 2015 during a trial with an investigational Prader-Willi syndrome drug, leading to discontinuation of the program. Zafgen subsequently merged with Larimar Therapeutics in 2020.“SLNO is at high risk of fading back into obscurity as a zombie biotech that trades near cash - $9/share - round-tripping back to single-digit or penny stock status, as it was a mere ~2.5 years ago when it hit 90 cents,” Scorpion Capital <a target="_blank" rel="noopener noreferrer nofollow" href="https://scorpionreports.s3.us-east-2.amazonaws.com/SLNO1.pdf">said</a> in its report. The firm further alleged that Soleno has “no meaningful assets, pipeline or scientific program, and its only drug is an inferior tablet version of a half-century-old suspension.”Scorpion Capital also stated that it intends to shortly submit an emergency Citizen Petition asking the FDA to request Soleno to conduct a voluntary recall of VYKAT XR from the market.Soleno <a href="https://stocktwits.com/news-articles/markets/equity/soleno-therapeutics-gets-fda-approval-for-prader-willi-syndrome-drug/chJ25DRRbE3">received</a> the U.S. Food and Drug Administration’s approval for Vykat XR extended-release tablets for the treatment of hyperphagia in patients four years of age and older with Prader-Willi syndrome in March and subsequently launched it in April. VYKAT XR is the company’s first commercial product.Prader-Willi syndrome is a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15, estimated to occur in one in every 15,000 live births. The disorder is defined by hyperphagia, an intense, persistent sensation of hunger, which could be life-threatening.Scorpion Capital has previously revealed short positions in multiple pharmaceutical and biotechnology companies, including Transmedics Group Inc (TMDX), Harmony Biosciences (HRMY), Twist Bioscience (TWST), and more.SLNO stock is up by 60% this year and by about 42% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/cleveland-cliffs-enters-multi-year-steel-deals-with-automakers-report/chsPDjERdfH">Cleveland-Cliffs Enters Multi-Year Steel Deals With Automakers, Says Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Soleno Therapeutics Stock Slumps After Scorpion Capital Reveals Short Position: But Retail’s Not Pessimistic Yet

The shortseller alleged several risks associated with Vykat XR, including high risk of pre-diabetes/diabetes, pulmonary edema, and congestive heart failure.

How Much Upside is Left in Soleno Therapeutics (SLNO)? Wall Street Analysts Think 43.15%

The average of price targets set by Wall Street analysts indicates a potential upside of 43.2% in Soleno Therapeutics (SLNO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Here's Why Momentum in Soleno Therapeutics (SLNO) Should Keep going

Soleno Therapeutics (SLNO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates

Soleno Therapeutics (SLNO) delivered earnings and revenue surprises of +83.02% and +1.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Soleno Therapeutics, Inc. (SLNO) is a Great Momentum Stock: Should You Buy?

Does Soleno Therapeutics, Inc. (SLNO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Can Soleno Therapeutics (SLNO) Climb 33.11% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Soleno Therapeutics (SLNO) points to a 33.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Soleno Therapeutics Inc

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

SLNO
Soleno Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest SLNO News

SLNO Soleno Therapeutics Inc